Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 99Head & Neck 2Thoracic 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 1364Lung Neoplasms 697Small Cell Lung Carcinoma 202Neoplasms 151Neoplasm Metastasis 130Breast Neoplasms 116Melanoma 99Colorectal Neoplasms 84Adenocarcinoma of Lung 84Ovarian Neoplasms 78Pancreatic Neoplasms 72Carcinoma, Renal Cell 69Head and Neck Neoplasms 66Mesothelioma 58Prostatic Neoplasms 53Urinary Bladder Neoplasms 52Mesothelioma, Malignant 51Stomach Neoplasms 47Triple Negative Breast Neoplasms 45Carcinoma 45Esophageal Neoplasms 43Brain Neoplasms 42Squamous Cell Carcinoma of Head and Neck 41Colonic Neoplasms 35Sarcoma 34Adenocarcinoma, Bronchiolo-Alveolar 33Recurrence 32Adenocarcinoma 31Uterine Cervical Neoplasms 30Parkinson Disease 4, Autosomal Dominant Lewy Body 29

Interventions

osimertinib 1cobimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Skin Neoplasms × Thoracic × Clear all
NCT03989115 2023-06-26

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

Revolution Medicines, Inc.

Phase 1/2 Completed
113 enrolled 22 charts
DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Urinary Bladder Neoplasms, Bronchial Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Gastrointestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Noonan Syndrome, Ovarian Neoplasms, Pancreatic Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Skin Neoplasms, Thoracic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡